Cipla US recalls anti-cancer capsules: FDA

Cipla USA, a subsidiary of the Indian pharmaceutical giant Cipla, has announced a recall of over 400 cartons of its Nilotinib Capsules, a generic anti-cancer medication, due to a manufacturing defect. The recall pertains to two specific strengths of the drug, 150 mg and 200 mg, as reported by the United States Food and Drug Administration (FDA). This action underscores the rigorous regulatory standards that pharmaceutical companies must adhere to in the U.S. market to ensure patient safety. Nilotinib is primarily used in the treatment of chronic myeloid leukemia (CML), a type of cancer that affects the blood and bone marrow. The recall reflects Cipla's commitment to quality assurance and patient safety, emphasizing the need for constant vigilance in drug manufacturing processes. As a leading player in the global pharmaceutical industry, Cipla's proactive measures in addressing potential health risks are crucial in maintaining public trust and ensuring compliance with health regulations. The FDA's involvement in this recall highlights the importance of regulatory oversight in safeguarding consumer health in the pharmaceutical sector.